Elevated Platelet Count Could Be a Biomarker for Several Cancers
Compared with patients who had a medium platelet count, patients with a very high platelet count had more than double the risk of a solid tumor diagnosis.
Home
Stopping Adjuvant Treatment Early May Decrease DFS, OS in Stage III Colon Cancer
Early treatment discontinuation was associated with a decrease in survival, but early oxaliplatin discontinuation was not.
Melflufen Improves PFS, Not OS in Relapsed/Refractory Multiple Myeloma
Melflufen prolonged progression-free survival when compared with pomalidomide.
Breast Cancer Survivors Face Higher Risk for Hypertension, Diabetes
The risk of hypertension was even higher for those receiving left-sided radiation or endocrine therapy.
Global Burden of Chronic Lymphocytic Leukemia Up From 1990 to 2019
The global burden of CLL increased from 40,537 cases in 1990 to 103,467 in 2019.
COVID-19 Rapid Test Makers Struggling to Meet Demand
The government’s order for the free test kits is in addition to the existing supply and does not interfere with existing orders.
First Positive First-Line Immuno-Chemotherapy Results for Biliary Tract Cancer
Adding durvalumab to gemcitabine and cisplatin improved progression-free and overall survival.
Eryaspase Does Not Improve PFS or OS in Advanced Pancreatic Cancer
The median overall survival was 7.5 months in the eryaspase arm and 6.7 months in the chemotherapy-alone arm.
STRIDE Regimen Extends Survival in Unresectable Hepatocellular Carcinoma
The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.
TACE Improves Efficacy of Lenvatinib in Advanced Hepatocellular Carcinoma
TACE improved responses and survival outcomes.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO GI 2022
Loading... 
Loading...